로딩 중…
지수 로딩 중…
L&C BIO Co.,LTD
290650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩45,900-0.65%
2026-09-18
Financials
Valuation Metrics
L&C BIO Co.,LTD's Market Cap is ₩1.2T. At end of 2025 it was ₩1.6T. Ranked #281 of 2,421 in KR market (top 12%), #74 of 1,640 on KOSDAQ (top 5%), #30 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.24T KRW | KR#281/2,421 Sec#30/231 |
| Revenue | 116.22B KRW | KR#1,332/2,421 Sec#84/231 |
| Net Income | -148.73B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 477.43B KRW | KR#790/2,421 Sec#46/231 |
| Net Assets | 335.19B KRW | KR#673/2,421 Sec#43/231 |
| Employees | 135 | KR#1,404/2,421 Sec#113/231 |
| Value | ||
| P/B | 3.69x | KR#2,172/2,421 Sec#176/231 |
| P/S | 10.65x | KR#2,286/2,421 Sec#167/231 |
| EV/EBITDA | 64.05x | KR#1,407/2,421 Sec#93/231 |
| FCF Yield | -0.26% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -44.37% | KR#2,257/2,421 Sec#192/231 |
| ROA | -31.15% | KR#2,323/2,421 Sec#203/231 |
| Op. Margin | 16.93% | KR#236/2,421 Sec#22/231 |
| Revenue Growth | 52.98% | KR#189/2,421 Sec#24/231 |
| Earnings Growth | -217.96% | KR#1,247/2,421 Sec#86/231 |
| Financial Health | ||
| Debt Ratio | 42.43% | KR#842/2,421 Sec#98/231 |
| Total Debt | 58.60B KRW | KR#941/2,421 Sec#63/231 |
| FCF | -3.25B KRW | KR#1,405/2,421 Sec#110/231 |
| Cash | 36.42B KRW | KR#893/2,421 Sec#59/231 |
| Current Ratio | 1.33x | KR#1,350/2,421 Sec#142/231 |
| Net Debt/EBITDA | 1.13x | KR#750/2,421 Sec#50/231 |
| Dividend | ||
| Div. Yield | 0.11% | KR#1,366/2,421 Sec#84/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -22.56% | KR#1,335/2,421 Sec#94/231 |
| 1M Return | -8.51% | KR#2,030/2,421 Sec#169/231 |
| From 52W High | -62.09% | KR#1,922/2,421 Sec#155/231 |
| 1Y MDD | -60.33% | KR#1,494/2,421 Sec#120/231 |
| Trading | ||
| Volume | 82,127 shares | KR#880/2,421 Sec#87/231 |
| Trading Value | 3.82B KRW | KR#420/2,421 Sec#43/231 |
| Foreign Own. | 24.69% | KR#168/2,421 Sec#6/231 |
| Per Share | ||
| EPS | -5,515 KRW | KR—/2,421 Sec—/231 |
| BPS | 12,428 KRW | KR#827/2,421 Sec#56/231 |
Company Info
동사는 2011년 설립된 조직공학 치료재료 전문 바이오 기업으로, 2018년 코스닥시장에 상장하였음. 연결대상 종속회사로 GMRC 등 4개사를 보유하고 있으며, 당분기 중 엘앤씨에이아이와 엘앤씨퓨처랩의 지분을 매각하였음. 동사는 인체조직이식재, 의료기기, 코스메슈티컬 제조·판매와 제약사업, 자회사 GMRC를 통한 기능성 화장품·건강기능식품 CRO사업, AI 화장품 추천 플랫폼 사업을 영위하고 있음. 엘앤씨바이오는 2011년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.